A study analyzing 69 patients with gastric neuroendocrine tumors (GNETs) showed a favorable prognosis, with 5-year survival rates at 93.8% and recurrence rates at 7.25%. Most tumors were grade 1 and type I, with treatment variations between tumor grades; grade 1 patients often opted for endoscopic treatment, while grade 2 received surgical or chemotherapeutic interventions. […]
Category: Sarcoma & rare tumors
Fluorescence imaging effectively locates small pancreatic tumors.
Fluorescence imaging using indocyanine green has shown promising results for the intraoperative localization of small pancreatic neuroendocrine tumors. In a case report involving five patients, successful tumor identification and laparoscopic partial resections were achieved without serious complications. Pathological reviews confirmed four neuroendocrine tumors of G1 stage and one case of neuroendocrine cell hyperplasia. The findings […]
PRRT enhances survival in patients after GEP-NET progression
Peptide receptor radionuclide therapy (PRRT) significantly improves progression-free survival (PFS) and overall survival (OS) in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who progress after surgical resection. Among 237 analyzed patients, those receiving PRRT experienced a median PFS of 32.4 months compared to 11.0 months for those who did not (p < 0.001). Median OS […]
Endoscopic ultrasonography-guided ethanol injections demonstrate efficacy for small pancreatic tumors
A prospective multicenter study evaluated endoscopic ultrasonography-guided ethanol injections (EUS-EI) for treating small pancreatic neuroendocrine neoplasms (PNENs). Of the 25 patients treated, 76% achieved the primary endpoint compared to surgical outcomes, and 88% attained complete ablation at 1 and 6 months. Safety results were promising, with 96% experiencing no severe adverse events within one month. […]
Mural nodules and intraluminal air predict neuroendocrine tumors.
Mural nodules protruding into the lumen and intraluminal air serve as significant predictors of neuroendocrine tumors in patients with acute appendicitis. In a study involving 1,150 patients, those with neuroendocrine tumors exhibited a mural nodule prevalence of 53.3% sensitivity and 95.8% specificity, while intraluminal air showed 53.3% sensitivity and 76.7% specificity. Incorporating these imaging indicators […]
New tool predicts liver metastasis risks in neuroendocrine tumors
A novel Liver Metastasis Score (LMS) effectively predicts liver metastasis risk for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) post-surgery. Among 724 patients studied, 9.1% developed liver metastasis, significantly impacting survival rates (63.6% vs. 95.8% for no metastasis). Key risk factors identified include Ki-67 index, vascular invasion, lymph node metastases, and absence of adjuvant therapy. The […]
Machine learning model predicts malignant potential of gastric tumors
A novel machine-learning model effectively predicts the malignant potential of gastric gastrointestinal stromal tumors (GISTs), identifying key risk factors such as endoscopic ultrasound features, tumor margin clarity, diameter, and monocyte-to-lymphocyte ratio. Tested with 318 patients, the logistic classification model achieved high performance with area under the curve values of 0.919 and 0.925 for training and […]
High preoperative HbA1c levels correlate with poorer outcomes in GEP-NET patients
Higher preoperative glycosylated hemoglobin A1C (HbA1c) levels significantly affect long-term outcomes in patients undergoing resection for nonfunctional gastroenteropancreatic neuroendocrine tumors (GEP-NETs). A study involving 190 patients revealed that those with HbA1c ≥ 6.5% experienced increased complications and markedly reduced median overall survival (89.8 months vs. not reached for low HbA1c). This association highlights the need […]
Surgery improves outcomes in metastatic neuroendocrine tumors
Evidence suggests that surgical intervention, prior to peptide receptor radionuclide therapy, significantly enhances progression-free survival for patients with metastatic gastroenteropancreatic neuroendocrine tumors. In a study of 89 well-matched patients, those who underwent surgery had a median progression-free survival of 26.1 months, compared to 15.6 months in the no-surgery group (p = .04). Furthermore, liver debulking […]
EUS-FNA/B shows strong diagnostic performance for PANNETs
A meta-analysis involving 2,978 patients confirms that endoscopic ultrasound-guided fine needle acquisition (EUS-FNA/B) is an effective method for diagnosing and pre-operatively grading pancreatic neuroendocrine tumors (PANNETs). The overall concordance rate with surgical grading was 0.77, with a notable increase in the G1 subgroup (0.88). Notably, fine needle biopsy (FNB) outperformed fine needle aspiration (FNA) in […]